Arash Soltani

List of Publications by Year
in descending order

24 papers	1,130 citations	516215 16 h-index	676716 22 g-index
24 all docs	24 docs citations	24 times ranked	1675 citing authors

#	Article	IF	Citations
1	PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomedicine and Pharmacotherapy, 2019, 110, 312-318.	2.5	204
2	Tumor-associated macrophages: role in cancer development and therapeutic implications. Cellular Oncology (Dordrecht), 2019, 42, 591-608.	2.1	161
3	Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie, 2019, 165, 229-234.	1.3	152
4	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
5	The thioredoxin system and cancer therapy: a review. Cancer Chemotherapy and Pharmacology, 2019, 84, 925-935.	1.1	72
6	Quercetin: A promising phytochemical for the treatment of glioblastoma multiforme. BioFactors, 2020, 46, 356-366.	2.6	72
7	Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 6337-6345.	2.0	49
8	A product-technology portfolio alignment approach for food industry: a multi-criteria decision making with z-numbers. British Food Journal, 2020, 122, 3947-3967.	1.6	46
9	Cytokines as potential combination agents with PD–1/PD–L1 blockade for cancer treatment. Journal of Cellular Physiology, 2020, 235, 5449-5460.	2.0	42
10	Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives. Journal of Cellular Physiology, 2018, 233, 4783-4790.	2.0	39
11	Oxidative stress in cervical cancer pathogenesis and resistance to therapy. Journal of Cellular Biochemistry, 2019, 120, 6868-6877.	1.2	33
12	5′-Adenosine monophosphate-activated protein kinase: A potential target for disease prevention by curcumin. Journal of Cellular Physiology, 2019, 234, 2241-2251.	2.0	28
13	Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives. Journal of Cellular Physiology, 2019, 234, 2329-2336.	2.0	26
14	Protective Role of Natural Products in Glioblastoma Multiforme: A Focus on Nitric Oxide Pathway. Current Medicinal Chemistry, 2020, 28, 377-400.	1.2	26
15	Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomedicine and Pharmacotherapy, 2019, 109, 770-778.	2.5	24
16	Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme. Current Medicinal Chemistry, 2021, 28, 4877-4892.	1.2	16
17	Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer. Molecular Biology Reports, 2021, 48, 4797-4811.	1.0	13
18	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. International Immunopharmacology, 2021, 98, 107870.	1.7	13

#	Article	IF	Citations
19	Emerging roles of microRNAs in regulating the mTOR signaling pathway during tumorigenesis. Journal of Cellular Biochemistry, 2019, 120, 10874-10883.	1.2	11
20	Evaluation of STAT1 and Wnt5a gene expression in gingival tissues of patients with periodontal disease. Journal of Cellular Biochemistry, 2019, 120, 1827-1834.	1.2	11
21	Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1879-1899.	1.1	10
22	The comparative study of the effects of Fe 2 O 3 and TiO 2 micro€•and nanoparticles on oxidative states of lung and bone marrow tissues and colony stimulating factor secretion. Journal of Cellular Biochemistry, 2019, 120, 7573-7580.	1.2	6
23	Application of Molecular Docking for the Development of Improved HIV-1 Reverse Transcriptase Inhibitors. Current Computer-Aided Drug Design, 2021, 17, 538-549.	0.8	0
24	Serum Procalcitonin and Lactoferrin in Detection of Acute Appendicitis; a Diagnostic Accuracy Study. Emergency, 2018, 6, e51.	0.6	0